SCHEMBL750438

SCHEMBL750438

Cc1nc(N)cc(-c2c(Nc3ccc(C(=O)Nc4ccccc4)cc3)nc3ccccn23)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 9/20 0.57
MTOR P42345 9/20 0.57
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
KMT2A Q03164 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
POLB P06746 1/20 0.41
DNMT1 P26358 1/20 0.41
DNMT3L Q9UJW3 1/20 0.41
DNMT3A Q9Y6K1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL756457 0.92 PIK3CA (0.56) PIK3CAMTORLMNARAB9ASMN1; SMN2
SCHEMBL2790005 0.92 PIK3CA (0.62) PIK3CAMTORCCNE1CDK2ALDH1A1
SCHEMBL752570 0.89 PIK3CA (0.61) PIK3CAMTORCDK2LMNAMAPT
SCHEMBL755730 0.88 PIK3CA (0.57) PIK3CAMTORCCNE1CDK2LMNA
SCHEMBL751862 0.88 PIK3CA (0.56) PIK3CAMTORMAPTKMT2AGAA
SCHEMBL11028397 0.87 PIK3CA (0.59) PIK3CAMTORCCNE1CDK2LMNA
SCHEMBL11027619 0.86 PIK3CA (0.60) PIK3CAMTORCCNE1CDK2MAPT
SCHEMBL2771022 0.85 PIK3CA (0.62) PIK3CAMTORCCNE1CDK2SMN1; SMN2
SCHEMBL2775861 0.84 PIK3CA (0.56) PIK3CAMTORCCNE1CDK2LMNA
SCHEMBL16161626 0.84 PIK3CA (0.56) PIK3CAMTORCCNE1CDK2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885CCNE1 1797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.